@FierceBiotech: Juventas snaps up business development veteran, more in this week's roundup of hirings and firings in biotech, pharma. More | Follow @FierceBiotech
@JohnCFierce: Odana is one of Merck's top PhIII drugs, and like suvorexant may not sell well against generics. Where's the breakthrough strategy? More | Follow @JohnCFierce
@RyanMFierce: Gilead hungers for more cancer drug deals. But Ariad? Story | Follow @RyanMFierce
> Elan ($ELN) has agreed to sell all of its remaining 7,750,000 ordinary shares of Alkermes through Jefferies & Company. Elan sold its Elan Drug Technologies (EDT) formulation and manufacturing business to Alkermes in a cash and shares deal valued at $960 million in 2011. Release
> Spectrum Pharmaceuticals' ($SPPI) stock jumped Thursday after the company said it regained rights from Allergan ($AGN) to market its bladder cancer drug apaziquone and is making progress with the FDA to consider the drug's approval. Story
> Researchers in China think a protein derived from pigs has potential to treat dementia patients. Story
Pharma News
@FiercePharma: Genzyme's $176K Kynamro price undercuts its $250K-plus rival. But rivalry in orphan drugs isn't the usual. Article | Follow @FiercePharma
@EricPFierce: Medicare refiguring how it will pay for dialysis drugs. It is part of the new payer world. More | Follow @EricPFierce
> U.K. gatekeepers shut out AZ and BMS' new diabetes drug. Story
> Merck has to trim outlook as pipeline poops out. Article
> Pfizer's Zoetis spinoff outshines drug biz, at least for a day. More
> OTC plant bites Novartis' reputation again. Report
@FierceMedDev: New special report: Top diagnostics VC investments of 2012. More | Follow @FierceMedDev
@MarkHFierce: Philips Healthcare had a solid Q4--the overall company, less so. More | Follow @MarkHFierce
@DamianFierce: Add Smith & Nephew to the list of companies cutting jobs and blaming the 2.3% medical device tax. Report | Follow @DamianFierce
> GE pursues 'corrective action' for more parts used in two infant warmers. Article
> Ivantis hauls in $27M for tiny eye stent. Story
> MITA: CMS should weigh Dx endpoints for beta amyloid PET imaging coverage. Item
And Finally... Could the study of folkloric beasts have a place in mainstream science? Story